Innovations in HIV Therapeutics 2022 - Asia-Pacific Edition

What's New

The advent of the COVID-19 pandemic has drastically changed the delivery of HIV care, but there is more on the horizon. New compounds with diverse modes of action and novel formulations have the potential to revolutionize HIV service delivery even more, as these may allow longer dosing schedules, increase adherence and improve cost-efficacy. Therefore, there is a continuous need for medical education on new (long-acting) antiretroviral therapies (ART), novel formulations, and devices to provide the best care. In contrast to existing educational activities that focus on approved or late-stage clinical data on ART, this program offers a platform entirely dedicated to HIV preclinical and early clinical development. This platform considered regional differences in health care systems, with a focus on the Asia-Pacific region.

Welcome

The Innovations in HIV Therapeutics - Asia Pacific Edition took place as a virtual meeting on 16 December 2022.

As the pipeline of HIV drugs continues to evolve and novel formulations and devices are on the horizon, the Innovation in HIV Therapeutics meeting provided a scientific program that keeps HIV-treating clinicians, pharmacologists, and virologists updated on the latest data present in preclinical and early clinical development. New formulations, novel compounds, and their modes of action were presented, as well as their pharmacological properties, potential drug-drug interactions, and possible toxicities.

This meeting was presented as a one-day program accounting for the unique regional differences present in the Asia Pacific region.

General Information

Practical Information